<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03919526</url>
  </required_header>
  <id_info>
    <org_study_id>SHSYXY-CAR-T MRD+ALL</org_study_id>
    <nct_id>NCT03919526</nct_id>
  </id_info>
  <brief_title>Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL</brief_title>
  <official_title>The Safety and Clinical Efficacy of Human CD19/CD22 Bispecific CAR-T Cell Therapy for Subjects With MRD-positive B Cell Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of CD19/CD22 Bispecific CAR-T for the treatment of&#xD;
      MRD-positive B cell acute lymphoblastic leukemia. Patients will be given a conditioning&#xD;
      chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of&#xD;
      CD19/CD22 CAR+ T cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with MRD-positive B cell acute lymphoblastic leukemia can participate if all&#xD;
      eligibility criteria are met. Tests required to determine eligibility include disease&#xD;
      assessments, a physical exam, Electrocardiograph, CT/MRI , and blood draws. Participants&#xD;
      receive chemotherapy prior to the infusion of CD19/CD22 CAR+ T cells. After the infusion,&#xD;
      participants will be followed for side effects and effect of CD19/CD22 CAR+ T cells. Study&#xD;
      procedures may be performed while hospitalized.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Anticipated">December 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 11, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by occurence of study related adverse effects defined by NCI CTCAE5.0</measure>
    <time_frame>28 days post infusion</time_frame>
    <description>Safety measured by occurence of study related adverse effects defined by NCI CTCAE5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRD clearance</measure>
    <time_frame>3 months post infusion</time_frame>
    <description>MRD clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Content of CD19 positive B-cells in peripheral blood</measure>
    <time_frame>3 months post infusion</time_frame>
    <description>Content of CD19 positive B-cells in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Content of CAR-T related cytokines positive T cells in circulation</measure>
    <time_frame>3 months post infusion</time_frame>
    <description>Content of CAR-T related cytokines positive T cells in circulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total response rate (ORR) after administration</measure>
    <time_frame>3 months post infusion</time_frame>
    <description>Total response rate (ORR) after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR) after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Duration of remission (DOR) after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Overall Survival (OS)after administration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>MRD-positive</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>anti-CD19/CD22 CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration with anti-CD19/ CD22 CAR-T cells in the MRD-positive ALL patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-CD19/CD22 CAR-T cells</intervention_name>
    <description>Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs</description>
    <arm_group_label>anti-CD19/CD22 CAR-T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30mg/m2/d</description>
    <arm_group_label>anti-CD19/CD22 CAR-T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>300mg/m2/d</description>
    <arm_group_label>anti-CD19/CD22 CAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) CD19 positive/CD22 positive, or CD19-CD22 positive B-cell acute lymphoblastic&#xD;
             leukemia;&#xD;
&#xD;
          -  (2)18 to 70 Years Old, Male and female;&#xD;
&#xD;
          -  (3) Expected survival &gt; 12 weeks;&#xD;
&#xD;
          -  (4) ECOG score 0-2;&#xD;
&#xD;
          -  (5) Bone marrow examination clearly diagnosed as B-cell acute lymphoblastic leukemia&#xD;
             and who met one of the following conditions:&#xD;
&#xD;
               1. Recurrent patients who achieves MRD-positive CR or CRi after standard therapy;&#xD;
&#xD;
               2. Those who achieves CR, but failed to achieve MRD-negative after at least 2&#xD;
                  courses of consolidation therapy;&#xD;
&#xD;
          -  (6) The venous access required for collection can be established and mononuclear cell&#xD;
             collection can be determined by the investigators;&#xD;
&#xD;
          -  (7) Liver, kidney and cardiopulmonary functions meet the following requirements:&#xD;
&#xD;
               1. Creatinine is in the normal range;&#xD;
&#xD;
               2. Left ventricular ejection fraction &gt;50%;&#xD;
&#xD;
               3. Baseline oxygen saturation&gt;92%;&#xD;
&#xD;
               4. Total bilirubin ≤ 2×ULN;&#xD;
&#xD;
               5. ALT and AST ≤ 2.5×ULN;&#xD;
&#xD;
          -  (8) Able to understand and sign the Informed Consent Document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) BCR-ABL fusion gene-positive patients;&#xD;
&#xD;
          -  (2) Malignant tumors other than acute lymphoblastic leukemia within 5 years prior to&#xD;
             screening, in addition to adequately treated cervical carcinoma in situ, basal cell or&#xD;
             squamous cell skin cancer, localized prostate cancer after radical resection, and&#xD;
             ductal carcinoma in situ after radical resection;&#xD;
&#xD;
          -  (3) Subjects with positive HBsAg or HBcAb and peripheral blood HBV DNA titer detection&#xD;
             ≥ 1 × 102 copy number / L; HCV antibody positive and peripheral blood HCV RNA&#xD;
             positive; HIV antibody positive; CMV DNA positive; syphilis positive;&#xD;
&#xD;
          -  (4) Any instability of systemic disease, including but not limited to unstable angina,&#xD;
             cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to&#xD;
             screening), myocardial infarction (within 6 months prior to screening), congestive&#xD;
             heart failure (New York heart association (NYHA) classification ≥ III), need drug&#xD;
             therapy of severe arrhythmia, liver, kidney, or metabolic disease;&#xD;
&#xD;
          -  (5) Active or uncontrollable infection requiring systemic therapy within 14 days prior&#xD;
             to enrollment;&#xD;
&#xD;
          -  (6) Pregnant or lactating woman, and female subject who plans to have a pregnancy&#xD;
             within 1 year after cell transfusion, or male subject whose partner plans to have a&#xD;
             pregnancy within 1 year after cell transfusion;&#xD;
&#xD;
          -  (7) Received CAR-T treatment or other gene therapies before enrollment;&#xD;
&#xD;
          -  (8) Patients with symptoms of central nervous system;&#xD;
&#xD;
          -  (9) Subjects who are receiving systemic steroid treatment and requiring long-term&#xD;
             systemic steroid treatment during the treatment as determined by the investigator&#xD;
             before screening (except inhalation or topical use); And subjects treated with&#xD;
             systemic steroids (except inhalation or topical use) within 72h prior to cell&#xD;
             transfusion;&#xD;
&#xD;
          -  (10) The investigators consider other conditions unsuitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xianmin Song, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xianmin Song, M.D.</last_name>
    <phone>021-63240090</phone>
    <email>shongxm@139.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongliang Fang, doctor</last_name>
    <phone>021-58552006</phone>
    <email>fanghongliang@dashengbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianmin Song, M.D.</last_name>
      <phone>86-21-63240090</phone>
      <phone_ext>3172</phone_ext>
      <email>shongxm@sjtu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 7, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Xianmin Song, MD</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>CD19/CD22</keyword>
  <keyword>Bispecific CAR-T</keyword>
  <keyword>leukemia</keyword>
  <keyword>MRD-positive</keyword>
  <keyword>B-ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

